Actively Recruiting
Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma
Led by Sun Yat-sen University · Updated on 2020-05-28
290
Participants Needed
1
Research Sites
734 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Low-grade glioma (LGG) is a common primary brain tumor in young adults. The infiltrative nature and frequent growth in eloquent area in brain often makes total resection impossible. Until now, no agreement has been achieved on the treatment of LGG without total resection. Post-radiation adjuvant temozolomide (TMZ) is currently the standard of care for high-grade gliomas. Radiotherapy or TMZ is recommended for the treatment of residue low-grade gliomas. However, the efficacy of combined radiotherapy with adjuvant TMZ for residue LGG remains to be defined. In this randomized controlled trial, the investigators will test the hypothesis that radiotherapy with subsequent TMZ chemotherapy is superior to improve the progression-free survival of patients with residue LGG without significant impairment to quality of life compared to radiotherapy alone.
CONDITIONS
Official Title
Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 60 years
- Diagnosis of incompletely resected supratentorial WHO grade II astrocytoma, oligodendroglioma, or oligodendroastrocytoma
- Karnofsky Performance Score of 60 or higher
- Adequate bone marrow, liver, and kidney function
- Ability to understand the trial and its consequences
- Provided written informed consent
You will not qualify if you...
- Refusal to participate in the study
- Known hypersensitivity or contraindication to temozolomide
- Previous radiation therapy, radiosurgery, or chemotherapy
- Pregnant or breastfeeding women
- Having a malignant tumor other than a brain tumor
- Contraindications to MRI examination
- Unable to comply with follow-up requirements of the trial
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China, 510060
Actively Recruiting
Research Team
Z
Zhong-ping CHEN, MD, PhD
CONTACT
K
Ke SAI, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here